This study compared the efficacy and tolerability of monotherapy with felodipine and enalapril in patients with essential hypertension using a double-blind randomised crossover design. Thirty-five subjects (22 male, 13 female-ages: median 48 years, range 31-69 years) entered the randomised phases of the study and 32 subjects completed the study. Following a 4-week run-in placebo phase, the treatments were felodipine ("Plendil ER" 5-20 mg and enalapril 5-20 mg orally once daily for 8 weeks, each with matching placebos. Dose titration was at 2 and/or 4 weeks in each phase. Number of subjects with each different end-of-phase dose were for felodipine: 5 mg-8, 10 mg-11, 20 mg-13 and enalapril: 5 mg-6, 10 mg-9, 20 mg-17. Predose supine blood pressure (mean SEM) was reduced in both active treatment phases compared wih the run-in phase (159 ±2/101 ± 1), but there was no significant difference in blood pressure between the active phases: felodipine 143±2/90±1 and enalapril 146±2/92±1. The most common adverse effects were for felodipine: headache, flushing, ankle swelling; and for enalapril: cough. Felodipine and enalapril as once daily monotherapy are thus of similar antihypertensive efficacy but with predictably different adverse effect profiles.
- Angiotensin-converting enzyme inhibitors
- Calcium channel blockers